Table 1 Participant characteristics.
Subject ID/category | Age range | Gender | ApoE | CSF Aβ42/40 | MCBP | Converter on follow-up MCBP? | Amyloid status during labeling study | CDR | Clinical diagnoses |
|---|---|---|---|---|---|---|---|---|---|
1: AD Amyloid Converter | 60–65 | M | 3/3 | 0.122 | 0.05 | Y | A− (PET); A+ (CSF-borderline) | 1 | DAT (9 years of clinical history) |
2: AD Amyloid [+] | 85–90 | M | 3/3 | 0.084 | N/A | N/A | A+ (CSF) (PET data unavailable) | 0.5 | DAT w/CVD not contributing; remote CVD (3 years of clinical history) |
3: AD Amyloid [−] | 65–70 | F | 3/3 | 0.208 | 0.01 | N/A | A− (PET); A− (CSF) | 0 | No dementia; remote mood disorder (8 years of clinical history) |
4: AD Amyloid [−] | 70–75 | M | 3/3 | 0.142 | 0.11 | N/A | A− (PET); A− (CSF) | 0 | No dementia |
5: AD Amyloid [−] | 65–70 | F | 3/3 | 0.200 | 0.04 | N | A− (PET); A− (CSF) | 0 | No dementia |
6: AD Amyloid [−] | 60–65 | M | 3/3 | 0.165 | 0.05 | N/A | A− (PET); A− (CSF) | 0 | Cognitively normal |
7: AD Amyloid [−] | 65–70 | F | 2/3 | 0.203 | 0.08 | N/A | A− (PET); A− (CSF) | 0 | Cognitively normal |
